{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:06:50Z","timestamp":1763136410085,"version":"3.45.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00192-025-06178-y","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:49:18Z","timestamp":1748242158000},"page":"2049-2054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Mirabegron and Propiverine Combination in the Treatment of Refractory Overactive Bladder"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-2293","authenticated-orcid":false,"given":"Mehmet Gokhan","family":"Culha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Sezgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Erkoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyyup","family":"Danis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre Can","family":"Polat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Otunctemur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"1","key":"6178_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4\u201320.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"6178_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1590\/s1677-5538.ibju.2023.0158","volume":"49","author":"W He","year":"2023","unstructured":"He W, et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023;49(5):535\u201363.","journal-title":"Int Braz J Urol"},{"issue":"4","key":"6178_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","volume":"8","author":"H Mostafaei","year":"2022","unstructured":"Mostafaei H, et al. Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. Eur Urol Focus. 2022;8(4):1072\u201389.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"6178_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324\u201333.","journal-title":"Eur Urol"},{"issue":"4","key":"6178_CR5","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388\u201395.","journal-title":"J Urol"},{"issue":"2","key":"6178_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"S Herschorn","year":"2013","unstructured":"Herschorn S, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b2\u2083 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313\u201320.","journal-title":"Urology"},{"issue":"Suppl 3","key":"6178_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s12262-015-1264-1","volume":"77","author":"W Huang","year":"2015","unstructured":"Huang W, et al. Efficacy and safety of propiverine hydrochloride for overactive bladder in adult: a systematic review and meta-analysis. Indian J Surg. 2015;77(Suppl 3):1369\u201377.","journal-title":"Indian J Surg"},{"issue":"1","key":"6178_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/bju.13500","volume":"119","author":"J Leng","year":"2017","unstructured":"Leng J, et al. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder. BJU Int. 2017;119(1):148\u201357.","journal-title":"BJU Int"},{"issue":"3","key":"6178_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iju.13868","volume":"26","author":"O Yamaguchi","year":"2019","unstructured":"Yamaguchi O, et al. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study). Int J Urol. 2019;26(3):342\u201352.","journal-title":"Int J Urol"},{"issue":"10","key":"6178_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10): e297.","journal-title":"PLoS Med"},{"issue":"2","key":"6178_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma Y, et al. Symptom assessment tool for overactive bladder syndrome\u2013overactive bladder symptom score. Urology. 2006;68(2):318\u201323.","journal-title":"Urology"},{"issue":"1","key":"6178_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.urology.2014.03.019","volume":"84","author":"Y Homma","year":"2014","unstructured":"Homma Y, Fujimura T. Psychometric validation of the English version of the overactive bladder symptom score. Urology. 2014;84(1):46\u201350.","journal-title":"Urology"},{"issue":"12","key":"6178_CR13","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00192-019-04054-0","volume":"30","author":"MG Culha","year":"2019","unstructured":"Culha MG, et al. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. Int Urogynecol J. 2019;30(12):2121\u20136.","journal-title":"Int Urogynecol J"},{"issue":"2","key":"6178_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/nau.23919","volume":"38","author":"ER Mueller","year":"2019","unstructured":"Mueller ER, et al. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourol Urodyn. 2019;38(2):779\u201392.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"6178_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/nau.25348","volume":"43","author":"S Jensen","year":"2024","unstructured":"Jensen S, et al. An observational, patient-reported outcome study of sleep quality and depression among individuals with overactive bladder syndrome. Neurourol Urodyn. 2024;43(2):437\u201348.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"6178_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","volume":"82","author":"AK Nambiar","year":"2022","unstructured":"Nambiar AK, et al. European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49\u201359.","journal-title":"Eur Urol"},{"issue":"8","key":"6178_CR17","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/nau.25532","volume":"43","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. Neurourol Urodyn. 2024;43(8):1742\u201352.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"6178_CR18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/nau.25538","volume":"43","author":"VW Nitti","year":"2024","unstructured":"Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: a pooled analysis. Neurourol Urodyn. 2024;43(8):1765\u201375.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"6178_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.euf.2023.03.008","volume":"9","author":"E Chartier-Kastler","year":"2023","unstructured":"Chartier-Kastler E, et al. Five-year results from the prospective, multicenter, observational SOUNDS study of patients with overactive bladder treated with the interstim system for sacral neuromodulation. Eur Urol Focus. 2023;9(5):765\u201372.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6178_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12955-018-0892-0","volume":"16","author":"S Herschorn","year":"2018","unstructured":"Herschorn S, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16(1):69.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"6178_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euf.2017.08.008","volume":"3","author":"W Gibson","year":"2017","unstructured":"Gibson W, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus. 2017;3(6):629\u201338.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"6178_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","volume":"74","author":"C Gratzke","year":"2018","unstructured":"Gratzke C, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol. 2018;74(4):501\u20139.","journal-title":"Eur Urol"},{"issue":"11","key":"6178_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.5414\/CP201782","volume":"50","author":"C Eltink","year":"2012","unstructured":"Eltink C, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b2\u2083-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838\u201350.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"6178_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.09.012","author":"A Dey","year":"2024","unstructured":"Dey A, et al. Mirabegron versus placebo and other therapeutic modalities in the treatment of patients with overactive bladder syndrome-a systematic review. Eur Urol Focus. 2024. https:\/\/doi.org\/10.1016\/j.euf.2024.09.012","journal-title":"Eur Urol Focus"},{"issue":"4","key":"6178_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"S Herschorn","year":"2017","unstructured":"Herschorn S, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562\u201375.","journal-title":"BJU Int"},{"issue":"1","key":"6178_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","volume":"70","author":"MJ Drake","year":"2016","unstructured":"Drake MJ, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136\u201345.","journal-title":"Eur Urol"},{"issue":"1","key":"6178_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/luts.12107","volume":"9","author":"O Yamaguchi","year":"2017","unstructured":"Yamaguchi O, Ikeda Y, Ohkawa S. Phase III study to assess long-term (52-week) safety and efficacy of mirabegron, a \u03b2(3) -adrenoceptor agonist, in Japanese patients with overactive bladder. Low Urin Tract Symptoms. 2017;9(1):38\u201345.","journal-title":"Low Urin Tract Symptoms"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-025-06178-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:01:51Z","timestamp":1763136111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-025-06178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6178"],"URL":"https:\/\/doi.org\/10.1007\/s00192-025-06178-y","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"260\/2023- Prof. Dr. Cemil Tascioglu City Hospital Ethical Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics of Approval"}},{"value":"Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}